bms-986196
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 12, 2021 (NCT04882150)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06034899 | Phase 1 | Sep 22, 2023 | Bristol-Myers Squibb |
| NCT05981963 | Phase 1 | Aug 17, 2023 | Bristol-Myers Squibb |
| NCT05891262 | Phase 1 | Jun 6, 2023 | Bristol-Myers Squibb |
| NCT05852769 | Phase 1 | May 31, 2023 | Bristol-Myers Squibb |
| NCT04882150 | Phase 1 | May 12, 2021 | Bristol-Myers Squibb |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 5 | 5 | 1 | 2021 |
1 organizations
Page 1 / 1